Understanding Genomics in Lung Cancer

December 26, 2019
Kristie L. Kahl
Kristie L. Kahl

Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.

In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Ed Kim to better understand genomics in lung cancer.

While a lung cancer diagnosis can be a lot to understand, genomics is a new aspect of the disease that patients should better understand, as it can affect treatment decisions as well.

In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Ed Kim to better understand genomics in lung cancer. To start, he explained a common misunderstanding in the lung cancer space — what exactly is the difference between genetic and genomic testing in cancer. In this episode, Kim also focuses on what biomarker testing consists of and how patients can learn more about genomics to become better informed.